Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

Tornesello, Anna Lucia; Tagliamonte, Maria; Tornesello, Maria Lina; Buonaguro, Luigi; Buonaguro, Luigi

doi:10.3390/cancers12041049

Cited by 60 publications

(49 citation statements)

References 100 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hao et al have conjugated the cell-penetrating peptide TAT to the C-terminus of HPRP-A1 peptide and obtained enhanced specificity against cancer cells [ 72 ]. The use of nanoparticles is a further example of delivery strategy optimization [ 73 ]. Pazos et al in 2016, designed a novel amphiphilic peptide with aldehydic properties which was capable to reduce silver ions and to nucleate silver nanoparticles in water.…”

Section: Critical Issues Possible Solutions For Clinical Use Of Amentioning

confidence: 99%

Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities

et al. 2020

Self Cite

View full text Add to dashboard Cite

Antimicrobial peptides (AMPs), or host defense peptides, are small cationic or amphipathic molecules produced by prokaryotic and eukaryotic organisms that play a key role in the innate immune defense against viruses, bacteria and fungi. AMPs have either antimicrobial or anticancer activities. Indeed, cationic AMPs are able to disrupt microbial cell membranes by interacting with negatively charged phospholipids. Moreover, several peptides are capable to trigger cytotoxicity of human cancer cells by binding to negatively charged phosphatidylserine moieties which are selectively exposed on the outer surface of cancer cell plasma membranes. In addition, some AMPs, such as LTX-315, have shown to induce release of tumor antigens and potent damage associated molecular patterns by causing alterations in the intracellular organelles of cancer cells. Given the recognized medical need of novel anticancer drugs, AMPs could represent a potential source of effective therapeutic agents, either alone or in combination with other small molecules, in oncology. In this review we summarize and describe the properties and the mode of action of AMPs as well as the strategies to increase their selectivity toward specific cancer cells.

show abstract

Section: Critical Issues Possible Solutions For Clinical Use Of Amentioning

confidence: 99%

Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…To address this issue, Cheng et al proposed a self-assembled delivery system for the PDT treatment of malignant melanoma [ 167 ]. The self-assembled nanocarrier system consists of the PS protoporphyrin, a melanoma-specific antigen peptide (KVPRNQDWL) [ 168 ], and PEG to achieve preferred tumor accumulation by EPR. PDT can enhance immunogenicity, improve the efficiency of antigen cross-presentation, and form more effective tumor-specific cytotoxic T cells.…”

Section: Nanoparticle-based Drug Delivery For Melanoma Therapeuticmentioning

confidence: 99%

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Song

Liu

Chen

et al. 2021

IJMS

View full text Add to dashboard Cite

Melanoma, as a tumor cell derived from melanocyte transformation, has the characteristics of malignant proliferation, high metastasis, rapid recurrence, and a low survival rate. Traditional therapy has many shortcomings, including drug side effects and poor patient compliance, and so on. Therefore, the development of an effective treatment is necessary. Currently, nanotechnologies are a promising oncology treatment strategy because of their ability to effectively deliver drugs and other bioactive molecules to targeted tissues with low toxicity, thereby improving the clinical efficacy of cancer therapy. In this review, the application of nanotechnology in the treatment of melanoma is reviewed and discussed. First, the pathogenesis and molecular targets of melanoma are elucidated, and the current clinical treatment strategies and deficiencies of melanoma are then introduced. Following this, we discuss the main features of developing efficient nanosystems and introduce the latest reports in the literature on nanoparticles for the treatment of melanoma. Subsequently, we review and discuss the application of nanoparticles in chemotherapeutic agents, immunotherapy, mRNA vaccines, and photothermal therapy, as well as the potential of nanotechnology in the early diagnosis of melanoma.

show abstract

“…Thus, of the six melanoma patients that were vaccinated, four showed no signs of tumor recurrence in a follow-up period of up to 32 months, providing a strong rationale for further refining this methodology. One logical approach would be to combine neoantigen-specific peptide vaccination with nanoparticular formulations [ 59 ]. For example, Luo and colleagues convincingly demonstrated the improved therapeutic potential of small (29 nm diameter) polymeric nanoparticles that were loaded with synthetic peptides [ 60 ].…”

Section: Personalized Anti-cancer Therapies and Nanotechnologymentioning

confidence: 99%

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

Bockamp

Rosigkeit

Siegl

et al. 2020

Cells

View full text Add to dashboard Cite

Cancer immunotherapy utilizes the immune system to fight cancer and has already moved from the laboratory to clinical application. However, and despite excellent therapeutic outcomes in some hematological and solid cancers, the regular clinical use of cancer immunotherapies reveals major limitations. These include the lack of effective immune therapy options for some cancer types, unresponsiveness to treatment by many patients, evolving therapy resistance, the inaccessible and immunosuppressive nature of the tumor microenvironment (TME), and the risk of potentially life-threatening immune toxicities. Given the potential of nanotechnology to deliver, enhance, and fine-tune cancer immunotherapeutic agents, the combination of cancer immunotherapy with nanotechnology can overcome some of these limitations. In this review, we summarize innovative reports and novel strategies that successfully combine nanotechnology and cancer immunotherapy. We also provide insight into how nanoparticular combination therapies can be used to improve therapy responsiveness, to reduce unwanted toxicity, and to overcome adverse effects of the TME.

show abstract

Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines

Cited by 60 publications

References 100 publications

Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities

Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities

Nanocarrier-Based Drug Delivery for Melanoma Therapeutics

Nano-Enhanced Cancer Immunotherapy: Immunology Encounters Nanotechnology

Contact Info

Product

Resources

About